HR Execs on the Move

Access Health CT

www.accesshealthct.com

 
Access Health CT is bringing the benefits of Health Care Reform to Connecticut. As the state`s official health insurance marketplace, we`re making it easier and more affordable for individuals, families, and small businesses to get quality health care coverage.
  • Number of Employees: 1K-5K
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Glenn Jurgen
Human Resources Director Profile

Similar Companies

YMCA of Greater Des Moines

Were for youth development, healthy living and social responsibility.

Audible Difference

Audible Difference is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bio-Ops

Bio-Ops is a Los Altos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eye Health Northwest

Eye Health Northwest is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KaloBios

KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.